Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?
Authors:
- 7 September 2024
- journal article
- research article
- Published by Elsevier in Seminars in Hematology
- Vol. 61 (5) , 297-305
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- The paths and challenges of “off-the-shelf” CAR-T cell therapy: An overview of clinical trialsBiomedicine & Pharmacotherapy, 2023
- Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment ResistanceLaboratory Investigation, 2023
- Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple MyelomaOncology and Therapy, 2023
- GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trialThe Lancet Haematology, 2023
- Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T CellsTransplantation and Cellular Therapy, 2022
- Senescent T cells: a potential biomarker and target for cancer therapyEBioMedicine, 2021
- Global Manufacturing of CAR T Cell TherapyMolecular Therapy - Methods & Clinical Development, 2017
- Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cellsMolecular Oncology, 2013
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironmentCurrent Opinion in Immunology, 2013
- T cell receptor specificity for major histocompatibility complex proteinsCurrent Opinion in Immunology, 2008